Wall Street analyst estimates for Protagonist Therapeutics, Inc. (PTGX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders.
Valuation Ratios
| Price / Book | 8.71 |
| EV / EBITDA | -42.43 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | $20.1M | $30.9M | $231000 | $28.6M | $27.4M | $26.6M | $60.0M | $434.4M | $46.0M |
| Cost of Revenue | $317000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.2M |
| Gross Profit | -$317000 | $20.1M | $30.9M | $231000 | $28.6M | $27.4M | $26.6M | $60.0M | $434.4M | $44.8M |
| Research & Development | $25.7M | $46.2M | $59.5M | $65.0M | $76.0M | $126.0M | $126.2M | $120.2M | $138.1M | $159.3M |
| Selling, General & Admin | $7.0M | $11.8M | $13.7M | $15.7M | $18.6M | $27.2M | $31.7M | $33.5M | $43.5M | $44.9M |
| Operating Expenses | $32.7M | $58.0M | $73.2M | $80.8M | $93.1M | $153.2M | $158.0M | $153.7M | $181.6M | $202.9M |
| Operating Income | -$32.7M | -$37.9M | -$42.3M | -$80.5M | -$64.5M | -$125.8M | -$131.4M | -$93.7M | $252.8M | -$158.1M |
| EBITDA | -$32.3M | -$36.6M | -$39.2M | -$77.0M | -$63.6M | -$122.8M | -$124.0M | -$75.6M | $280.2M | -$128.1M |
| Interest Expense | 0 | 0 | 0 | $169000 | $598000 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$37.2M | -$37.0M | -$39.7M | -$77.9M | -$64.8M | -$125.6M | -$127.4M | -$79.0M | $279.4M | -$129.3M |
| Income Tax | 0 | 0 | -$799000 | -$691000 | $1.3M | 0 | 0 | 0 | $4.2M | $838000 |
| Net Income | -$37.2M | -$37.0M | -$38.9M | -$77.2M | -$66.2M | -$125.6M | -$127.4M | -$79.0M | $275.2M | -$130.1M |
| EPS | $-5.72 | $-2.09 | $-1.74 | $-2.98 | $-1.92 | $-2.65 | $-2.52 | $-1.39 | $4.47 | $-2.05 |
| EPS (Diluted) | $-5.72 | $-2.09 | $-1.74 | $-2.98 | $-1.92 | $-2.65 | $-2.52 | $-1.39 | $4.23 | $-2.05 |
| Shares Outstanding (Diluted) | $6.5M | $17.7M | $22.4M | $25.9M | $34.4M | $46.3M | $49.0M | $56.8M | $65.1M | $63.6M |
Price
| Price | $142.84 |
| Market Cap | $9.2B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACLX · AKRO · ALKS · CRNX · IMVT · KYMR · NAMS
Explore sector: Healthcare · Biotechnology
More sections of PTGX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks